A preclinical study conducted by a joint team from Switzerland has found that treatment outcomes for glioblastoma patients improve considerably if they receive immunotherapy before undergoing surgery to remove the tumors, instead of first having the tumors surgically removed and then receiving immunotherapy. The study, which was reported in a recent press release, suggests that the timing of immunotherapy relative to surgery could be a critical factor in fighting this aggressive form of brain cancer.
Glioblastoma is known for its poor prognosis and resistance to conventional therapies. Standard treatment typically involves surgical resection followed by chemotherapy and radiation. The addition of immunotherapy has shown promise in some cancers, but its efficacy in glioblastoma has been limited. This new research indicates that delivering immunotherapy in the neoadjuvant setting—before surgery—may prime the immune system to better recognize and attack tumor cells that are left behind, thereby improving overall survival.
The study’s findings are likely to give enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) plenty to think about as they continue to develop immunotherapies for cancer. Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation oncolytic virus and stem cell-based therapies for solid tumors. The company’s approach often involves using modified viruses or stem cells to deliver therapeutic agents to tumors, which may complement or enhance the effects of immunotherapy. The results of this preclinical study could inform the design of future clinical trials and treatment protocols, potentially leading to more effective combination strategies.
The research underscores the importance of timing in cancer treatment. By administering immunotherapy before surgery, the immune system may be activated while the tumor is still present, allowing it to mount a more robust response. This is in contrast to the conventional approach where immunotherapy is given after surgery, when the tumor has been removed and the immune system may not have a clear target. The findings also highlight the need for further investigation into the optimal sequencing of treatments for glioblastoma and other cancers.
For patients, these results offer hope that new treatment strategies may extend survival and improve quality of life. For the medical community, the study emphasizes the need to reconsider standard protocols and to explore the potential of neoadjuvant immunotherapy in clinical practice. As research progresses, it will be important to validate these findings in human trials and to identify biomarkers that can predict which patients are most likely to benefit from this approach.
The study adds to a growing body of evidence that the immune system plays a crucial role in fighting cancer and that its manipulation can lead to significant clinical benefits. It also reinforces the value of collaborative research efforts across institutions and disciplines. As companies like Calidi Biotherapeutics continue to innovate in the field of immunotherapy, insights from such preclinical studies will be instrumental in shaping the future of cancer treatment.
